Top Abstract Purchase Related
Home
>
Node
>
Subnode

Duodenal absorption of a low molecular weight heparin in rabbits

Doutremépuich, C.; Masse, A.; Oca, C.; Maury, M.O.; Gestreau, J.L.; Toulemonde, F.; Lormeau, J.C.

Pathologie-Biologie 32(1): 45-48

1984

ISSN/ISBN: 0369-8114
PMID: 6701007
Document Number: 231408
Commercial heparin cannot practically cross the intestinal barrier. Meanwhile, because of the theoretical interest in oral heparin therapeutics, we applied our studies to a low molecular weight heparin fraction (3 000 to 4 000 D). This fraction was directly injected into anaesthetized rabbit duodenum. For an equal anticoagulant activity (expressed in international units), commercial heparin is not absorbed whereas the low molecular weight fraction mainly induces an early plasmatic anti-Xa activity which remains over the fifth hour.

Document emailed within 1 workday
Secure & encrypted payments

Godoy, I.; Herrera, C.; Zapata, C.; Kunstmann, S.; Abufhele, A.; Corbalán, R. 1998: Comparison of low-molecular-weight heparin and unfractionated heparin in the treatment of unstable angina Revista Medica de Chile 126(3): 259-264
Párama, J.A.; Llorens, R.; Sáenz de Buruaga, J.; Rocha, E. 1994: Low-molecular-weight heparin in a patient with heparin-induced thrombocytopenia and a cardiopulmonary bypass Medicina Clinica 102(16): 637-638
Bannon, P.G.; Kim, M.J.; Dean, R.T.; Dawes, J. 1995: Augmentation of vascular endothelial barrier function by heparin and low molecular weight heparin Thrombosis and Haemostasis 73(4): 706-712
Huisse, M.G.; Huet, Y.; Zygelman, M.; Guillin, M.C. 1983: Thrombopenia induced by standard heparin. Therapeutic attempt using a low molecular weight heparin Presse Medicale 12(10): 643
Uzan, A.; Marin, J.; Mardiguian, J.; Trillou, M.; Kiosseff, T.; Rougeot, C. 1987: Comparative pharmacokinetic study, in the dog, of low molecular weight heparin and standard heparin by labelling with 35S Annales Pharmaceutiques Francaises 45(6): 429-437
Eriksson, E.; Wollter, I.M.; Christenson, B.; Stigendal, L.; Risberg, B. 1988: Heparin and fibrinolysis--comparison of subcutaneous administration of unfractionated and low molecular weight heparin Thrombosis and Haemostasis 59(2): 284-288
Kaiser, B.; Hauptmann, J.; Markwardt, F. 1988: Experimental studies on the antithrombotic and haemorrhagic effects of heparin and a low molecular weight heparin derivative Folia Haematologica 115(1-2): 119-125
Nakagawa, M. 1993: Heparin, low molecular weight heparin, heparinoid, and antithrombin IIi therapy of disseminated intravascular coagulation Nihon Rinsho. Japanese Journal of Clinical Medicine 51(1): 87-92
Bârzu, T.; Molho, P.; Tobelem, G.; Petitou, M.; Caen, J.P. 1984: Binding of heparin and low molecular weight heparin fragments to human vascular endothelial cells in culture Nouvelle Revue Francaise d'Hematologie 26(4): 243-247
Morita, Y.; Makino, H.; Ota, K.; Wada, J.; Shikata, K.; Kashihara, N.; Ikeda, S.; Ogura, T.; Ota, Z. 1994: Effect of heparin and low-molecular-weight heparin on proliferative glomerulonephritis Nihon Jinzo Gakkai Shi 36(7): 832-838
Chigot, P.; De Gennes, C.; Samama, M.M. 1996: Osteoporosis induced either by unfractionated heparin or by low molecular weight heparin Journal des Maladies Vasculaires 21(3): 121-125
Gouault-Heilmann, M.; Contant, G.; Pochmalicki, G.; Jan, F. 1984: Disseminated intravascular coagulation induced by heparin. Treatment with a combination of low-molecular weight heparin and concentrated antithrombin IIi Presse Medicale 13(22): 1393-1394
Mätzsch, T.; Bergqvist, D.; Blomquist, P.; Jiborn, H. 1987: Influence of standard heparin or low molecular weight heparin on healing of abdominal wounds and colonic anastomoses in rats Acta Chirurgica Scandinavica 153(10): 593-598
Hull, R.D.; Raskob, G.E.; Rosenbloom, D.; Pineo, G.F.; Lerner, R.G.; Gafni, A.; Trowbridge, A.A.; Elliott, C.G.; Green, D.; Feinglass, J. 1997: Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective Archives of Internal Medicine 157(3): 289-294
Mousa, S.A.; Fareed, J. 2001: Overview: from heparin to low molecular weight heparin: beyond anticoagulation Current Opinion in Investigational Drugs 2(8): 1077-1080
Wu, X.-x.; Chen, Y.; Tan, J.-p.; Liu, M.-l.; Zhang, J.-p. 2013: Modulation of low molecular weight heparin and heparin-binding epidermal growth factor on biological functions of human first trimester trophoblast Zhonghua Fu Chan Ke Za Zhi 48(2): 107-112
Osterkorn, D.; Schramm, W.; Szucs, T. 1996: Health care economics evaluation of inpatient treatment of venous thrombosis with unfractionated heparin versus subcutaneous low molecular weight heparin at home Medizinische Klinik 91(9): 607-609
Neri Serneri, G.G. 1993: Heparin, low-molecular-weight heparin and their clinical use Annali Italiani di Medicina Interna: Organo Ufficiale Della Societa Italiana di Medicina Interna 8(2): 69-72
Grunebaum, L.; Fricker, J.P.; Wiesel, M.L.; Vergnes, Y.; Kapps, J.; Cazenave, J.P. 1987: Preliminary results of a randomized trial comparing the efficacy of standard heparin with that of fragmine, a low molecular weight heparin, in the prevention of postoperative thrombosis in cancer surgery Journal des Maladies Vasculaires 12 Suppl B: 102-104
Hirsh, J. 1993: Low molecular weight heparin Thrombosis and Haemostasis 70(1): 204-207